Targeted therapy in advanced non-small-cell lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 29, Issue 3, 2008, Pages 291-301

  Gettinger, Scott ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Non small cell lung cancer (NSCLC); Vascular endothelial growth factor (VEGF)

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AMG 655; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CP 751871; DOCETAXEL; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PEMETREXED; SORAFENIB; SUNITINIB; TANESPIMYCIN HYDROQUINONE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VORINOSTAT;

ANGIOGENESIS; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TOXICITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; HUMANS; INDOLES; LUNG NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINAZOLINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44349128964     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1076749     Document Type: Review

References (77)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167
3. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005;32:315-328
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected] J Clin Oncol 2003;21:2237-2246
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
8. Lee DH, Han JY, Yu SY, et al. The role of gefitinib treatment for Korean never smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006;1:965-971
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
11. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
12. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006;95:1483-1489
13. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346
14. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective srudy of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-389
15. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7020
16. Shepherd FA, Tsao M-S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006;24:1219-1220
17. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144
18. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042
19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17
20. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552
23. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794
24. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784
25. Herbst RS, Chansky K, Kelly K, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7545
26. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. ASCO Meeting Abstracts. 2003;22:2581
27. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts. July 15, 2004;22(14 Suppl):7012
28. Butts CA, Bodkin D, Middleman EL, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7539
29. Jalal SI, Waterhouse D, Edelman M, et al. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hoosier Oncology Group. ASCO Meeting Abstracts. June 20, 2007;25(18_suppl):7698
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578
31. Blumenschein G Jr, Moughan J, Curran W, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): an interim report of the RTOG 0324 trial. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7531
32. Socinski MA. Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab. Clin Cancer Res 2007;13:4597s-4601
33. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64:5355-5362
34. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487-6501
35. Okabe T, Okamoto I, Tamura K, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007;67:2046-2053
36. Naret CL, Ramalingam S, Beattie L, et al. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):17045
37. Baselga J, Schoffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):3006
38. Preston GG, Calvo E, Papadopoulos K, et al. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):3005
39. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410
40. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158
41. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
42. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191
43. Hurwitz LI, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
44. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7535
45. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803
46. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7002
47. Schiller JH, Flaherty KT, Redlinger M, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7194
48. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7001
49. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7542
50. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. ASCO Meeting Abstracts. June 20, 2006;24(18Suppl): 7000
51. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7016
52. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530
53. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560
54. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-1210
55. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556
56. Guy SP, Ashton S, Hughes G, et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models [abstract B13]. Clin Cancer Res 2003;9(Suppl):6142s
57. Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7062
58. Davies AM, Lara PN Jr, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4647-s4651
59. Schenkein DP. Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 2004;6(Suppl 2): S89-S96
60. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-2511
61. Stevenson JP, Nho CW, Johnson SW, et al. Effects of bortezomib (PS-341) on NF-{kappa}B activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a phase II/pharmaco-dynamic trial. ASCO Meeting Abstracts. July 15, 2004; 22(14 Suppl):7145
62. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033
63. Davies AM, McCoy J, Lara P N Jr, et al. Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II Southwest Oncology Group (SWOG) trial (S0339). ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7017
64. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216
65. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-7300
66. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 2006;7:309-312
67. Ramalingam SS, Parise RA, Ramananthan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13:3605-3610
68. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7507
69. McKeage M, Investigators ASSG. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2006;24(18 Suppl):7102
70. Bepler G, Oh Y, Burris H, Cleverly A, Lahn M, Herbst RS. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7543
71. Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7575
72. Karp DD, Paz-Ares LG, Blakely LJ, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2007; 25(18 Suppl):7506
73. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):3534
74. Papadimitrakopoulou V, Blumenschein G, Fossella F, et al. O-287 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC). Abstract of the 10th World Conference on Lung Cancer. Lung Cancer 2003;41(Suppl 2):S83-S84
75. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-s4654
76. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. June 20, 2007;25(18 Suppl):7554
77. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-4730